Radiology Question for the Week of May 16, 2022


What decision was made in regard to the final coverage for monoclonal antibodies and amyloid PET?


First, understand that FDA-approved monoclonal antibodies are antibodies that are used against amyloid for the purposes of Alzheimer’s disease treatment. The service occurs under Coverage with Evidence Development (CED) in FDA-approved, CMS-approved, or NIH-sponsored controlled trials with the national coverage determination (NCD) originally proposed in January. CMS finalized the decision to include no additional coverage for beta-amyloid PET scans. Even more, the PET scans will remain under the present policy, which contains massive restrictions including providing coverage only when meeting requirements for clinical trial protocol. Note that the restriction imposed is limited to only one per patient per lifetime. The decision by CMS is a blow to the many groups including radiology stakeholders like the Society of Nuclear Medicine and Molecular Imaging (SNMMI) who have put forth effort into Alzheimer’s disease advocacy, promoting some rebuke.

This question was answered in an edition of our Radiology Compliance Manager. For more hot topics relating to radiology services, please visit our store or call us at 1.800.252.1578, ext. 2.

Print Friendly, PDF & Email

CPT® copyright 2022 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.